Microbix Biosystems granted U.S. patent for its influenza vaccine yield enhancement technology
According to the company, Microbix' discovery has enormous implications for protecting more people during a pandemic. Patents are also being allowed in Canada, India and Australia, and a number of other applications in major markets are currently pending.
"We're delighted that we now have strong patent protection as we engage in assisting manufacturers increase production" said William J. Gastle, CEO of Microbix. The company's technology will be licensed to manufacturers on a non-exclusive basis.
VIRUSMAX(TM) can be implemented quickly and cost-effectively by manufactures, allowing them to ramp up production in a matter of months. Microbix has established a Special Workgroup for Applied Technology Transfer (SWATT) to help manufacturers adopt the process. The SWATT team is now being sent to various facilities to assist customers in implementing the technology and training local personnel.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.